thebench.bio #1 Ecosystem for the Bio-Tech Industry

Industry Daily Summary

Industry Daily Summary: What Happened on November 3, 2026

Stryker invests $400 million in CMR Surgical and gains option to buy it

AstraZeneca set a cost-cutting target, Karyopharm entered bankruptcy and the FDA set a decision date for uniQure’s Huntington’s disease therapy.

  • Updated
  • Read from 3 articles, 3 publications
  • P

Today in brief

Stryker will invest about $400 million in CMR Surgical, gain exclusive US commercial rights to its Versius robots and hold an option to acquire the company.1 AstraZeneca is targeting $1.5 billion in annual savings by 2029. The FDA set May 1, 2027, as its decision date for uniQure’s Huntington’s disease application.2

Stryker backs CMR Surgical and could acquire the company

Stryker will invest about $400 million in CMR Surgical and gain exclusive US commercial rights to CMR’s Versius surgical robotics portfolio.1 Stryker also secured an option to buy all of CMR’s outstanding equity in a later transaction, subject to the agreement’s terms.1

CMR will continue developing Versius and selling it outside the US.1 The investment and commercial arrangement still needs regulatory approval and must meet customary closing conditions.1

Also worth knowing

  • The UK Health Security Agency awarded Bavarian Nordic a four-year contract to supply MVA-BN, a vaccine used to prevent mpox and smallpox.3

  • Karyopharm filed for Chapter 11 bankruptcy on November 2. Ayrmid agreed to act as lead bidder in a potential acquisition, which requires court approval and remains open to competing offers.2

  • Dosing the fifth participant in a European Phase 3 study of Sanofi’s Nuvaxovid with a high-dose flu vaccine triggered a $125 million milestone payment to Novavax.2

Also published